Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin specific peptidase 32 pseudogene 3 (USP32P3) is classified as a pseudogene, meaning it is a segment of DNA that resembles a gene but is generally nonfunctional due to mutations that prevent it from encoding a protein. Pseudogenes like USP32P3 do not function as protein-coding genes and are not known to act as receptors, enzymes, or other canonical therapeutic targets. While some pseudogenes can have regulatory effects on gene expression, including acting as decoys for microRNAs or being processed into regulatory RNAs, there is no evidence that USP32P3 itself performs these functions, nor is it currently considered a biomarker or therapeutic target. USP32P3 shares sequence similarity with the protein-coding gene USP32 (ubiquitin specific peptidase 32), but does not produce a functional enzyme or protein. No drugs, mechanisms of action, or clinical safety concerns are associated with USP32P3.
None (for therapeutic drugs; pseudogenes do not encode active protein products)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin specific peptidase 32 pseudogene 3 (USP32P3).